PMID- 36607422
OWN - NLM
STAT- MEDLINE
DCOM- 20240221
LR  - 20240221
IS  - 1435-1250 (Electronic)
IS  - 0340-1855 (Linking)
VI  - 83
IP  - Suppl 1
DP  - 2024 Feb
TI  - Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab 
      in patients with active rheumatoid arthritis: a network meta-analysis of 
      randomized controlled trials.
PG  - 97-106
LID - 10.1007/s00393-022-01315-0 [doi]
AB  - OBJECTIVE: This study compared the relative efficacy and safety of olokizumab, 
      tocilizumab, and sarilumab in rheumatoid arthritis (RA) patients who were 
      intolerant or responding inadequately to methotrexate (MTX). METHODS: We 
      performed a Bayesian network meta-analysis to combine direct and indirect 
      evidence from randomized controlled trials (RCTs) to examine the efficacy and 
      safety of olokizumab, tocilizumab, and sarilumab in RA patients who were 
      intolerant or responding inadequately to MTX. RESULTS: Six RCTs comprising 
      4439 patients met the inclusion criteria. Tocilizumab, sarilumab, olokizumab, and 
      adalimumab treatments achieved a significant American College of Rheumatology 20% 
      (ACR20) response rate compared with placebo. However, tocilizumab was associated 
      with the most favorable surface area using the cumulative ranking curve (SUCRA) 
      for the ACR20 response rate. The ranking probability based on the SUCRA indicated 
      that tocilizumab treatment had the highest probability of providing the best 
      ACR20 response rate, followed by sarilumab, olokizumab every 2 weeks (Q2W), 
      olokizumab Q4W, adalimumab 40 mg, and placebo. The ACR50 and 70 response rates 
      showed a distribution pattern similar to that of the ACR20 response rate. 
      However, olokizumab Q4W had a higher ranking probability than olokizumab Q2W. The 
      SUCRA rating showed that the placebo was the best intervention with the least 
      adverse events (AEs) and withdrawal due to AEs, followed by interleukin‑6 
      inhibitors. CONCLUSION: Tocilizumab, sarilumab, and olokizumab are more effective 
      than adalimumab and have similar efficacy and safety in RA patients with 
      inadequate responses to MTX.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, 
      ein Teil von Springer Nature.
FAU - Ho Lee, Young
AU  - Ho Lee Y
AD  - Department of Rheumatology, Korea University College of Medicine, Seoul, Korea 
      (Republic of). lyhcgh@korea.ac.kr.
AD  - Division of Rheumatology, Department of Internal Medicine, Korea University Anam 
      Hospital, Korea University College of Medicine, 73, Goryeodae-ro, 02841, 
      Seongbuk-gu, Seoul, Korea (Republic of). lyhcgh@korea.ac.kr.
FAU - Gyu Song, Gwan
AU  - Gyu Song G
AD  - Department of Rheumatology, Korea University College of Medicine, Seoul, Korea 
      (Republic of).
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
TT  - Vergleich der Wirksamkeit und Sicherheit von Tocilizumab, Sarilumab und 
      Olokizumab bei Patienten mit aktiver rheumatoider Arthritis: Netzwerk-Metaanalyse 
      von randomisierten kontrollierten Studien.
DEP - 20230106
PL  - Germany
TA  - Z Rheumatol
JT  - Zeitschrift fur Rheumatologie
JID - 0414162
RN  - I031V2H011 (tocilizumab)
RN  - PAI71R1D2W (olokizumab)
RN  - NU90V55F8I (sarilumab)
RN  - FYS6T7F842 (Adalimumab)
RN  - 0 (Antirheumatic Agents)
RN  - YL5FZ2Y5U1 (Methotrexate)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Humans
MH  - Adalimumab/adverse effects
MH  - *Antirheumatic Agents/adverse effects
MH  - Network Meta-Analysis
MH  - Treatment Outcome
MH  - Bayes Theorem
MH  - Randomized Controlled Trials as Topic
MH  - *Arthritis, Rheumatoid/diagnosis/drug therapy
MH  - Methotrexate/adverse effects
MH  - Drug Therapy, Combination
MH  - *Antibodies, Monoclonal, Humanized
OTO - NOTNLM
OT  - Network meta-analysis
OT  - Olokizumab
OT  - Rheumatoid arthritis
OT  - Sarilumab
OT  - Tocilizumab
EDAT- 2023/01/07 06:00
MHDA- 2024/02/21 11:22
CRDT- 2023/01/06 11:14
PHST- 2022/12/12 00:00 [accepted]
PHST- 2024/02/21 11:22 [medline]
PHST- 2023/01/07 06:00 [pubmed]
PHST- 2023/01/06 11:14 [entrez]
AID - 10.1007/s00393-022-01315-0 [pii]
AID - 10.1007/s00393-022-01315-0 [doi]
PST - ppublish
SO  - Z Rheumatol. 2024 Feb;83(Suppl 1):97-106. doi: 10.1007/s00393-022-01315-0. Epub 
      2023 Jan 6.